139 related articles for article (PubMed ID: 16324692)
1. Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala.
Hill MN; Ho WS; Meier SE; Gorzalka BB; Hillard CJ
Eur J Pharmacol; 2005 Dec; 528(1-3):99-102. PubMed ID: 16324692
[TBL] [Abstract][Full Text] [Related]
2. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus.
Hill MN; Carrier EJ; Ho WS; Shi L; Patel S; Gorzalka BB; Hillard CJ
Hippocampus; 2008; 18(2):221-6. PubMed ID: 18058925
[TBL] [Abstract][Full Text] [Related]
3. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis.
Hill MN; McLaughlin RJ; Morrish AC; Viau V; Floresco SB; Hillard CJ; Gorzalka BB
Neuropsychopharmacology; 2009 Dec; 34(13):2733-45. PubMed ID: 19710634
[TBL] [Abstract][Full Text] [Related]
4. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
5. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts.
Wagner JA; Abesser M; Harvey-White J; Ertl G
J Cardiovasc Pharmacol; 2006 May; 47(5):650-5. PubMed ID: 16775503
[TBL] [Abstract][Full Text] [Related]
6. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity.
Hill MN; Barr AM; Ho WS; Carrier EJ; Gorzalka BB; Hillard CJ
J Neurochem; 2007 Oct; 103(1):47-56. PubMed ID: 17561935
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid/Endocannabinoid signaling impact on early pregnancy events.
Sun X; Dey SK
Curr Top Behav Neurosci; 2009; 1():255-73. PubMed ID: 21104387
[TBL] [Abstract][Full Text] [Related]
8. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue.
Ryan D; Drysdale AJ; Pertwee RG; Platt B
Eur J Neurosci; 2007 Apr; 25(7):2093-102. PubMed ID: 17419758
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents.
Hill MN; Ho WS; Hillard CJ; Gorzalka BB
J Neural Transm (Vienna); 2008 Dec; 115(12):1673-9. PubMed ID: 18974922
[TBL] [Abstract][Full Text] [Related]
10. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
Hill MN; Carrier EJ; McLaughlin RJ; Morrish AC; Meier SE; Hillard CJ; Gorzalka BB
J Neurochem; 2008 Sep; 106(6):2322-36. PubMed ID: 18643796
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoids: The silent partner of glucocorticoids in the synapse.
Hill MN; McEwen BS
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4579-80. PubMed ID: 19293387
[No Abstract] [Full Text] [Related]
12. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area.
Mátyás F; Urbán GM; Watanabe M; Mackie K; Zimmer A; Freund TF; Katona I
Neuropharmacology; 2008 Jan; 54(1):95-107. PubMed ID: 17655884
[TBL] [Abstract][Full Text] [Related]
13. Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice.
Bowles NP; Hill MN; Bhagat SM; Karatsoreos IN; Hillard CJ; McEwen BS
Neuroscience; 2012 Mar; 204():83-9. PubMed ID: 21939741
[TBL] [Abstract][Full Text] [Related]
14. Localization of an endocannabinoid system in the hypophysial pars tuberalis and pars distalis of man.
Yasuo S; Unfried C; Kettner M; Geisslinger G; Korf HW
Cell Tissue Res; 2010 Nov; 342(2):273-81. PubMed ID: 20957495
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress.
Hill MN; Patel S; Carrier EJ; Rademacher DJ; Ormerod BK; Hillard CJ; Gorzalka BB
Neuropsychopharmacology; 2005 Mar; 30(3):508-15. PubMed ID: 15525997
[TBL] [Abstract][Full Text] [Related]
16. Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo.
Hill MN; Karatsoreos IN; Hillard CJ; McEwen BS
Psychoneuroendocrinology; 2010 Oct; 35(9):1333-8. PubMed ID: 20399021
[TBL] [Abstract][Full Text] [Related]
17. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.
Jeong WI; Osei-Hyiaman D; Park O; Liu J; Bátkai S; Mukhopadhyay P; Horiguchi N; Harvey-White J; Marsicano G; Lutz B; Gao B; Kunos G
Cell Metab; 2008 Mar; 7(3):227-35. PubMed ID: 18316028
[TBL] [Abstract][Full Text] [Related]
18. Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas).
Rademacher DJ; Weber DN; Hillard CJ
Neurotoxicology; 2005 Jan; 26(1):9-15. PubMed ID: 15527869
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala.
Serrano A; Rivera P; Pavon FJ; Decara J; Suárez J; Rodriguez de Fonseca F; Parsons LH
Alcohol Clin Exp Res; 2012 Jun; 36(6):984-94. PubMed ID: 22141465
[TBL] [Abstract][Full Text] [Related]
20. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism.
Carrier EJ; Kearn CS; Barkmeier AJ; Breese NM; Yang W; Nithipatikom K; Pfister SL; Campbell WB; Hillard CJ
Mol Pharmacol; 2004 Apr; 65(4):999-1007. PubMed ID: 15044630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
